NO873213L - Fremgangsmaate for fremstilling av transdermale preparater. - Google Patents

Fremgangsmaate for fremstilling av transdermale preparater. Download PDF

Info

Publication number: NO873213L
Authority: NO; Norway
Prior art keywords: linoleic acid; propylene glycol; skin; ester; triacetide
Prior art date: 1986-08-01

Application number

NO873213A

Other languages

English (en)

Norwegian (no)

Other versions

NO873213D0 (no

Inventor

Majid Mahjour

Mahdi B Fawzi

Uma Iyer

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-08-01

Filing date

1987-07-31

Publication date

1988-02-02

1987-07-31 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

1987-07-31 Publication of NO873213D0 publication Critical patent/NO873213D0/no

1988-02-02 Publication of NO873213L publication Critical patent/NO873213L/no

Links

238000002360 preparation method Methods 0.000 title claims description 17
238000000034 method Methods 0.000 title claims description 15
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 60
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 22
235000020778 linoleic acid Nutrition 0.000 claims description 22
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 22
229940079593 drug Drugs 0.000 claims description 18
239000003814 drug Substances 0.000 claims description 18
150000002148 esters Chemical class 0.000 claims description 13
239000002904 solvent Substances 0.000 claims description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 6
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
235000019197 fats Nutrition 0.000 claims description 4
JXNPEDYJTDQORS-HZJYTTRNSA-N (9Z,12Z)-octadecadien-1-ol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCO JXNPEDYJTDQORS-HZJYTTRNSA-N 0.000 claims description 3
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
JXNPEDYJTDQORS-UHFFFAOYSA-N linoleyl alcohol Natural products CCCCCC=CCC=CCCCCCCCCO JXNPEDYJTDQORS-UHFFFAOYSA-N 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 2
239000002202 Polyethylene glycol Substances 0.000 claims 2
229920001223 polyethylene glycol Polymers 0.000 claims 2
150000001875 compounds Chemical class 0.000 description 15
239000000203 mixture Substances 0.000 description 15
230000035699 permeability Effects 0.000 description 11
238000009472 formulation Methods 0.000 description 10
230000035515 penetration Effects 0.000 description 10
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
229960002288 procaterol Drugs 0.000 description 8
FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 8
239000000730 antalgic agent Substances 0.000 description 7
230000004907 flux Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 6
239000000496 cardiotonic agent Substances 0.000 description 6
235000004626 essential fatty acids Nutrition 0.000 description 6
150000004665 fatty acids Chemical group 0.000 description 6
239000012528 membrane Substances 0.000 description 6
229960005118 oxymorphone Drugs 0.000 description 6
229940124630 bronchodilator Drugs 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
238000009792 diffusion process Methods 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
229940035676 analgesics Drugs 0.000 description 4
230000000694 effects Effects 0.000 description 4
229960002428 fentanyl Drugs 0.000 description 4
IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 4
WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 4
229960001410 hydromorphone Drugs 0.000 description 4
238000011835 investigation Methods 0.000 description 4
229960005181 morphine Drugs 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
230000000202 analgesic effect Effects 0.000 description 3
230000002500 effect on skin Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
LZULAZTXJLWELL-UHFFFAOYSA-N methyl hex-5-ynoate Chemical compound COC(=O)CCCC#C LZULAZTXJLWELL-UHFFFAOYSA-N 0.000 description 3
230000003533 narcotic effect Effects 0.000 description 3
229960002789 procaterol hydrochloride Drugs 0.000 description 3
239000001069 triethyl citrate Substances 0.000 description 3
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 3
235000013769 triethyl citrate Nutrition 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
239000000168 bronchodilator agent Substances 0.000 description 2
BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
230000003177 cardiotonic effect Effects 0.000 description 2
239000006184 cosolvent Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
239000004254 Ammonium phosphate Substances 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
239000004348 Glyceryl diacetate Substances 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
KVJFJCFBPWWMBE-UHFFFAOYSA-N acetic acid propane-1,2-diol Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)CO KVJFJCFBPWWMBE-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
235000020661 alpha-linolenic acid Nutrition 0.000 description 1
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229910000148 ammonium phosphate Inorganic materials 0.000 description 1
235000019289 ammonium phosphates Nutrition 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
229940031016 ethyl linoleate Drugs 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
235000019443 glyceryl diacetate Nutrition 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
229960004488 linolenic acid Drugs 0.000 description 1
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000004084 narcotic analgesic agent Substances 0.000 description 1
230000008693 nausea Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO873213A 1986-08-01 1987-07-31 Fremgangsmaate for fremstilling av transdermale preparater. NO873213L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US89311986A	1986-08-01	1986-08-01

Publications (2)

Publication Number	Publication Date
NO873213D0 NO873213D0 (no)	1987-07-31
NO873213L true NO873213L (no)	1988-02-02

Family

ID=25401065

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO873213A NO873213L (no)	1986-08-01	1987-07-31	Fremgangsmaate for fremstilling av transdermale preparater.

Country Status (9)

Country	Link
EP (1)	EP0255485A3 (da)
JP (1)	JPS6399008A (da)
KR (1)	KR880002506A (da)
AU (1)	AU583466B2 (da)
DK (1)	DK400487A (da)
FI (1)	FI873310A7 (da)
NO (1)	NO873213L (da)
PT (1)	PT85458B (da)
ZA (1)	ZA875317B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4788064A (en) *	1987-07-31	1988-11-29	Warner-Lambert Company	Transdermal delivery system
CH679119A5 (da) *	1988-05-13	1991-12-31	Sandoz Ag
DK0431519T3 (da) *	1989-12-04	1994-07-04	Searle & Co	System til transdermal indgivelse af albuterol
US5149719A (en) *	1990-04-27	1992-09-22	Minnesota Mining And Manufacturing Company	Composition for transdermal penetration of medicaments
KR100413202B1 (ko) *	1994-11-17	2004-04-13	도레이 가부시끼가이샤	경피흡수제제
EA006384B1 (ru) *	2000-07-31	2005-12-29	Нюкомед Данмарк А/С	Композиция фентанила для интраназального введения
GB0300531D0 (en)	2003-01-10	2003-02-12	West Pharm Serv Drug Res Ltd	Pharmaceutical compositions
KR101539801B1 (ko)	2007-12-12	2015-07-27	데이고꾸세이약꾸가부시끼가이샤	록소프로펜 함유 수성 첩부제
JP2012188602A (ja) *	2011-03-12	2012-10-04	Yokohama Yushi Kogyo Kk	油脂組成物及び油脂組成物の製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU556817B2 (en) *	1982-02-03	1986-11-20	Efamol Limited	Topical application of a lithium salt and dihomo-alpha- linolenic acid
US4584299A (en) *	1984-05-21	1986-04-22	Warner-Lambert Company	Method of treating heart failure and medicaments therefor
US4626539A (en) *	1984-08-10	1986-12-02	E. I. Dupont De Nemours And Company	Trandermal delivery of opioids
US4616022A (en) *	1984-08-17	1986-10-07	Warner-Lambert Company	Procaterol stabilization
DE3500103C2 (de) *	1985-01-04	1987-01-22	R.P. Scherer GmbH, 6930 Eberbach	Pharmazeutische Zubereitung mit einem in Wasser und Verdauungssäften schwer löslichen Wirkstoff
DE3531545A1 (de) *	1985-09-04	1987-03-05	Goedecke Ag	Arzneimittel mit einem gehalt an calcium-antagonisten und deren verwendung

1987
- 1987-07-20 ZA ZA875317A patent/ZA875317B/xx unknown
- 1987-07-27 EP EP87810423A patent/EP0255485A3/en not_active Withdrawn
- 1987-07-29 AU AU76271/87A patent/AU583466B2/en not_active Expired - Fee Related
- 1987-07-29 FI FI873310A patent/FI873310A7/fi not_active Application Discontinuation
- 1987-07-30 PT PT85458A patent/PT85458B/pt unknown
- 1987-07-31 DK DK400487A patent/DK400487A/da not_active Application Discontinuation
- 1987-07-31 JP JP62190542A patent/JPS6399008A/ja active Pending
- 1987-07-31 NO NO873213A patent/NO873213L/no unknown
- 1987-08-01 KR KR1019870008461A patent/KR880002506A/ko not_active Abandoned

Also Published As

Publication number	Publication date
EP0255485A3 (en)	1988-03-30
KR880002506A (ko)	1988-05-09
AU583466B2 (en)	1989-04-27
NO873213D0 (no)	1987-07-31
PT85458A (en)	1987-08-01
JPS6399008A (ja)	1988-04-30
FI873310L (fi)	1988-02-02
DK400487A (da)	1988-02-02
PT85458B (en)	1989-12-11
DK400487D0 (da)	1987-07-31
FI873310A7 (fi)	1988-02-02
FI873310A0 (fi)	1987-07-29
AU7627187A (en)	1988-02-04
EP0255485A2 (en)	1988-02-03
ZA875317B (en)	1988-01-25

Publication	Publication Date	Title
EP0261429B1 (en)	1990-06-06	Penetration enhancement systems and the preparation thereof
Kikwai et al.	2005	In vitro and in vivo evaluation of topical formulations of spantide II
US5314685A (en)	1994-05-24	Anhydrous formulations for administering lipophilic agents
US20090182004A1 (en)	2009-07-16	Imiquimod formulation
PT503988E (pt)	2000-06-30	Composicoes para o tratamento de onicomicoses
JPH107584A (ja)	1998-01-13	サイクロスポリン含有外用剤およびその製造方法
CA1200497A (en)	1986-02-11	Penetrating topical pharmaceutical compositions containing 9-(2-hydroxyethoxymethyl) guanine
JP2923503B2 (ja)	1999-07-26	軟質ゼラチンカプセル剤
FI112777B (fi)	2004-01-15	Valmistusmenetelmä antivirus-aktiiviselle farmaseuttiselle öljy-vedessä emulsiolle, jossa on 9-[(2-hydroksietoksi)-metyyli]-guaniini (asyklovir) tai sen suola tai esteri
CA3198046A1 (en)	2022-05-27	Compositions and methods for deep dermal drug delivery
NO873213L (no)	1988-02-02	Fremgangsmaate for fremstilling av transdermale preparater.
KR950006217B1 (ko)	1995-06-12	니코란딜 외용제
WO1995004551A1 (en)	1995-02-16	Percutaneously absorbable preparation
JPH11349451A (ja)	1999-12-21	育毛剤
JPH0764754B2 (ja)	1995-07-12	経皮吸収促進剤及びこれを含有する皮膚外用剤
US5128135A (en)	1992-07-07	Percutaneous or trans-mucosal absorption enhancers, preparations containing the enhancers, and a method of preparing thereof
US5248674A (en)	1993-09-28	Percutaneous administration of 3'-azide'-deoxythymidine
DK2797599T3 (da)	2019-01-14	Fremgangsmåde og forbedret farmaceutisk sammensætning til forstærkning af transdermal levering af pde-5 inhibitor
JPH05117141A (ja)	1993-05-14	副腎エキス含有消炎鎮痛ゲル剤
US9925194B2 (en)	2018-03-27	Kinetin/zeatin topical formulation
KR20240164788A (ko)	2024-11-20	항염증 및 진통 활성을 갖는 국소 약학적 조성물 및 이의 용도
JPH0772133B2 (ja)	1995-08-02	安定なケトプロフエン含有クリ−ム製剤
JPH05148146A (ja)	1993-06-15	水溶性ゲル外用剤
JPH02152921A (ja)	1990-06-12	経皮吸収外用製剤
KR20000066357A (ko)	2000-11-15	케토롤락 외용제제